close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade
Kodu・Aktsiate loetelu・Nanobiotix
Search

Nanobiotix

Suletud

18.1 5.36

Osta

Hinna uuendus 22. jaan 2026, 16:29 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.08

Max

18.16

Põhinäitajad

By Trading Economics

Sissetulek

-5.4M

Müük

27M

Kasumimarginaal

-20.208

Töötajad

103

EBITDA

1.1M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+32.03% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. apr 2026

Turustatistika

By TradingEconomics

Turukapital

875M

Eelmine avamishind

12.74

Eelmine sulgemishind

18.1

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. jaan 2026, 23:49 UTC

Suurimad hinnamuutused turgudel

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

DJ

Loe

21. jaan 2026, 21:12 UTC

Suurimad hinnamuutused turgudel

Automaker Stocks Rise After Trump Calls Off European Tariffs

DJ

Loe

21. jaan 2026, 21:00 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

DJ

Loe

21. jaan 2026, 20:29 UTC

Suurimad hinnamuutused turgudel

Chip Makers Gain After Trump Calls Off European Tariffs

DJ

Loe

21. jaan 2026, 20:04 UTC

Suurimad hinnamuutused turgudel

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

DJ

Loe

21. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

DJ

Loe

21. jaan 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

DJ

Loe

21. jaan 2026, 22:39 UTC

Tulu

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

DJ

Loe

21. jaan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Loe

21. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

21. jaan 2026, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

DJ

Loe

21. jaan 2026, 21:19 UTC

Tulu

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

DJ

Loe

21. jaan 2026, 20:45 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Borse Group to Acquire Allfunds for $6.19B

DJ

Loe

21. jaan 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

DJ

Loe

21. jaan 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

DJ

Loe

21. jaan 2026, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

DJ

Loe

21. jaan 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

21. jaan 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

DJ

Loe

21. jaan 2026, 20:26 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

DJ

Loe

21. jaan 2026, 20:23 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

DJ

Loe

21. jaan 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

DJ

Loe

21. jaan 2026, 20:19 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse Group Agrees to Buy Allfunds

DJ

Loe

21. jaan 2026, 20:08 UTC

Tulu

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

DJ

Loe

21. jaan 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

DJ

Loe

21. jaan 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

DJ

Loe

21. jaan 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

DJ

Loe

21. jaan 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

DJ

Loe

21. jaan 2026, 19:24 UTC

Tulu

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

DJ

Loe

21. jaan 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

DJ

Loe

21. jaan 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

DJ

Loe

Nanobiotix Prognoos

Hinnasiht

By TipRanks

32.03% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR  32.03%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Keskpikk perspektiiv

Weak Bearish Evidence

Bearish events outweigh bullish events.

Pikk perspektiiv

Weak Bearish Evidence

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
help-icon Live chat